Intrinsiqq
Bastide Le Confort Médical logo

Bastide Le Confort Médical Quality Score

BLC.XPAR

⊜ Compare
Quality51

Business quality is the primary weakness (avg 33/100). Valuation is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
271.4x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
100/100
3.4x

Under 20x cash flow, well covered

Revenue Growth
0/100
1.6%

Below 2%, essentially flat

Cash Flow Growth
100/100
126.6%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
60/100
1.6%

Mild dilution under 2%

Margin Trend
70/100
+1.0pp

Slight expansion, directionally positive

Capital Structure
0/100
€386M

Net debt/FCF of 9.2x, high leverage

2022
€22.0M
€419M
2023
€37.0M
€427M
2024
€24.0M
€409M
2025
€25.0M
€411M
CashDebt
Return on Capital
0/100
4.6%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Bastide Le Confort Médical (BLC.XPAR) quality: score, margins and returns

Bastide Le Confort Médical (BLC.XPAR) scores 51/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 9.2% operating margins and 4.6% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Bastide Le Confort Médical (BLC.XPAR) a high-quality business?+

Bastide Le Confort Médical scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 9.2% operating margin and a 4.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Bastide Le Confort Médical's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BLC.XPAR's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Bastide Le Confort Médical scores well and where it falls behind.

What is Bastide Le Confort Médical's return on invested capital (ROIC)?+

Bastide Le Confort Médical earns about 4.6% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BLC.XPAR's margins and growth on this scorecard to judge durability.

How profitable is Bastide Le Confort Médical?+

Bastide Le Confort Médical runs an operating margin of about 9.2% and a net margin of about 0.3%. Revenue has grown at roughly 2.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

How the market compares: US profitability statistics

Peers

Medical Distribution · Pick stocks to compare with BLC.XPAR

CompareIntrinsic value
BOI.XPARBoiron SA
€19.05+1.33%41
VETO.XPARVetoquinol SA
€87.80+2.45%58
ALCGM.XPARCegedim S.A.
€9.81+1.87%80
EQS.XPAREquasens Société anonyme
€28.05+4.86%71
LBIRD.XPARLumibird
€24.05-3.41%57
GBT.XPARGuerbet SA
€6.26-0.95%38
ALERS.XPAREurobio Scientific S.A.
€26.35+0.00%38
EAPI.XPAREuroapi S.A.S.U.
€0.82+2.11%46

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BLC.XPAR

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.